Our translational platform can support your preclinical drug development by helping you select a candidate from your lead compound library. HUB Organoids™ are patient-derived models that preserve original tissue morphology and pathophysiology. Importantly they accurately predict patient response in the clinic and therefore can be effectively used as patient avatars in Phase II-like “clinical trials in a dish” (CTiD) to stratify your patient population. HUB Organoids allow you to:
Our biobank represents the main pillar of our CTiD translational platform as it is a living repository of patient-derived models that recapitulates the heterogeneity of the patient population.
Established models include more than 1000 HUB Organoids™ derived from patients with monogenic diseases, cancer patients, or patients with other inflammatory conditions such as chronic inflammatory lung disease (COPD) and inflammatory bowel disease (IBD)
Our monogenic disease organoid collection includes:
The HUB living organoid biobank also has an important representation of cancer models including:
HUB Organoids™ can support clinical trials in “co-clinical” applications whereby organoids are developed from patient biopsies while they are enrolled in a clinical trial (Phase I to III). In this settings HUB Organoids are treated similarly to patients in the clinic to:
The development of next-generation sequencing has contributed to shifting the focus from a “drug-centric” to a “patient-centric” view of therapeutic development whereby each patient is treated with a personalised approach, tailored to the molecular pathology of their disease. HUB Organoid Technology is contributing to making personalized medicine a reality for an increasing number of patients by faithfully recapitulating patient disease in vitro with organoid models that can be established directly from patient tissue and propagated for drug testing in a matter of weeks.